Skip to Main Content

The Japanese government is probing a scandal over allegations that Bayer may have improperly instructed a former sales rep to gather patient data that was used to prepare medical journal papers for promoting its Xarelto blood thinner, according to Pharma Japan.

The Ministry of Health, Labor, and Welfare is reportedly examining whether the company continued to use the papers — which might actually constitute promotional materials — after these were withdrawn in 2016. If Bayer had done so, the drug maker might have violated a law regarding false and misleading advertising, the web site explained.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!